|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.20 ILa | -1.38% |
|
-6.65% | -47.70% |
| 06-02 | Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab | CI |
| 05-20 | Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 198.7 | 239.8 | 265.8 |
| Spread/Res. | -20.89% | -34.45% | -40.86% |
| Spread/Supp. | -0.19% | -0.19% | +16.25% |
| Support | 157.5 | 157.5 | 135.23 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- EVGN Stock
- Charts Evogene Ltd.
Select your edition
All financial news and data tailored to specific country editions
